A 6-Month Follow-up Pilot Study in Patients with Organic Erectile Dysfunction.
By: Yoram Vardi *, Boaz Appel, Giris Jacob, Omar Massarwi, Ilan Gruenwald
In the past decade, phosphodiesterase 5 inhibitors (PDE5-Is) have become available for the treatment of erectile dysfunction (ED). However, their effect is still limited to the sexual act and probably do not improve spontaneous erections. These limitations are probably due to their inability to improve penile blood flow for a time period that is sufficient to allow optimal oxygenation and recovery of cavernosal vasculature. Recently, the effect of long-term daily use of PDE5-Is on endothelial function (EnF) has been shown to induce a short-term improvement in erectile function (EF) but probably not a longstanding one [1–3]. Read More